PMID: 3767146Nov 1, 1986Paper

Intravenous propafenone for termination of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, crossover study

Annals of Internal Medicine
E N ShenR J Sung

Abstract

To assess the antiarrhythmic efficacy of intravenous propafenone, 20 patients with inducible sustained supraventricular tachycardia received propafenone, 2 mg/kg body weight, or placebo in a double-blind, randomized, crossover study. Three patients had intra-atrial reentrant tachycardia, 3 had atrioventricular nodal reentrant tachycardia, and 14 had atrioventricular reciprocating tachycardia associated with the Wolff-Parkinson-White syndrome. Termination of supraventricular tachycardia occurred in 15 of the 20 patients receiving propafenone but 0 of the 11 patients receiving placebo (p less than 0.01). Propafenone prolonged refractoriness and slowed conduction of the atrium, the atrioventricular node, and accessory atrioventricular bypass tracts, and these effects provided antiarrhythmic action to halt tachycardia. No adverse effects were observed in any patient. We conclude that intravenous propafenone is safe and effective in the acute treatment of various forms of reentrant supraventricular tachycardia.

Citations

Jun 1, 1990·Cardiovascular Drugs and Therapy·P Puech, J P Gagnol
Nov 11, 1998·The American Journal of Cardiology·S C ReimoldE M Antman
Nov 11, 1998·The American Journal of Cardiology·A P Rae
Apr 1, 1996·Journal of Cardiovascular Electrophysiology·A O Grant
Feb 1, 1988·Chest·E C Huycke, R J Sung
Jul 1, 1991·The American Journal of Cardiology·C RostagnoG Bertini
May 15, 1989·The American Journal of Cardiology·J A VitaE M Antman
Feb 1, 1992·The American Journal of the Medical Sciences·U Birgersdotter-Green
Mar 1, 1988·Postgraduate Medicine·W T LaiR J Sung
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·M Valderrábano, B N Singh
Feb 22, 1990·The New England Journal of Medicine·C Funck-BrentanoD M Roden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.